On August 10th, Shin Jae-hoon, a researcher at Hanwha Investment & Securities, announced, "We are raising the target price of SK Chemicals to 450,000 KRW, reflecting the expected performance of SK Bioscience, a subsidiary of SK Chemicals, in the COVID-19 vaccine CMO business."
Over the past five days, individual investors have net sold 227,163 shares of SK Chemicals, while foreign investors and institutions have net bought 29,286 shares and 158,992 shares, respectively.

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
